KR20230104117A - 붕산계 화합물 - Google Patents

붕산계 화합물 Download PDF

Info

Publication number
KR20230104117A
KR20230104117A KR1020237008849A KR20237008849A KR20230104117A KR 20230104117 A KR20230104117 A KR 20230104117A KR 1020237008849 A KR1020237008849 A KR 1020237008849A KR 20237008849 A KR20237008849 A KR 20237008849A KR 20230104117 A KR20230104117 A KR 20230104117A
Authority
KR
South Korea
Prior art keywords
compound
mmol
added
mixture
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237008849A
Other languages
English (en)
Korean (ko)
Inventor
동후이 친
Original Assignee
파에노 테라퓨틱스 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파에노 테라퓨틱스 씨오., 엘티디. filed Critical 파에노 테라퓨틱스 씨오., 엘티디.
Publication of KR20230104117A publication Critical patent/KR20230104117A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237008849A 2020-08-20 2021-08-20 붕산계 화합물 Pending KR20230104117A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010845001.1 2020-08-20
CN202010845001 2020-08-20
CN202110373982.9 2021-04-07
CN202110373982 2021-04-07
PCT/CN2021/113815 WO2022037680A1 (zh) 2020-08-20 2021-08-20 硼酸类化合物

Publications (1)

Publication Number Publication Date
KR20230104117A true KR20230104117A (ko) 2023-07-07

Family

ID=80322587

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237008849A Pending KR20230104117A (ko) 2020-08-20 2021-08-20 붕산계 화합물

Country Status (7)

Country Link
US (1) US12590108B2 (https=)
EP (1) EP4201942A4 (https=)
JP (1) JP2023538645A (https=)
KR (1) KR20230104117A (https=)
CN (1) CN116615431A (https=)
TW (1) TW202214261A (https=)
WO (1) WO2022037680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技(杭州)有限公司 新的硼酸类化合物的晶型及其制备方法
WO2025228222A1 (zh) * 2024-04-30 2025-11-06 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其应用
WO2026067428A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 硼酸衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
US9012491B2 (en) * 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
CN105026407B (zh) * 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
US20180051041A1 (en) * 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2894251T3 (es) * 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos

Also Published As

Publication number Publication date
WO2022037680A1 (zh) 2022-02-24
TW202214261A (zh) 2022-04-16
US12590108B2 (en) 2026-03-31
CN116615431A (zh) 2023-08-18
US20240294554A1 (en) 2024-09-05
EP4201942A1 (en) 2023-06-28
JP2023538645A (ja) 2023-09-08
EP4201942A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
TWI761961B (zh) 稠合吡啶酮類化合物及其製備方法和應用
TW202304911A (zh) 吡啶醯胺類化合物
JP7403661B2 (ja) Khk阻害効果を有する化合物
KR20230104117A (ko) 붕산계 화합물
CN114846008B (zh) 具有果糖激酶(khk)抑制作用的嘧啶类化合物
AU2018345523A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
CN104994844A (zh) 硼酸衍生物及其治疗用途
CA3101373A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
AU669948B2 (en) Bicyclic amine derivatives
WO2019093450A1 (ja) ジアザビシクロオクタン誘導体
KR20220127900A (ko) Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도
CN121487922A (zh) Ras抑制剂的合成
CN116234551A (zh) 一类1,7-萘啶类化合物及其应用
KR20220053637A (ko) 치환된 우레아 다이하이드로오로테이트 탈수소효소 억제제
KR102921812B1 (ko) 피리딘 유도체 및 이의 용도
KR20210124328A (ko) Pd-l1 면역조절제인 플루오로 비닐 벤즈아미드 화합물
TW202309013A (zh) 酮類衍生物
FR2542316A1 (fr) Procede de preparation de derives carbapenem, nouveaux intermediaires de synthese et procede de preparation de ces intermediaires
US20230126480A1 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
CS414991A3 (en) Optically pure (5r, 6s, 1'r) configured 6-(1-hydroxyethyl)-2-methoxymethylpenem-3-carboxylic acid, process of its preparation and a pharmaceutical comprising said acid
TWI829432B (zh) 用於治療細菌感染之唍脒單環內醯胺(monobactam)化合物
CN116425770A (zh) 作为Cdc7抑制剂的四并环类化合物
TWI297689B (en) Novel β-lactam compounds and process for producing the same
KR20220084398A (ko) 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
CN119841826B (zh) 二氮杂二环类β-内酰胺酶抑制剂及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902